Details
| Stereochemistry | MIXED |
| Molecular Formula | C14H30O4S |
| Molecular Weight | 294.451 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O
InChI
InChIKey=GROJOWHVXQYQGN-UHFFFAOYSA-N
InChI=1S/C14H30O4S/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17/h12-14H,5-11H2,1-4H3,(H,15,16,17)
| Molecular Formula | C14H30O4S |
| Molecular Weight | 294.451 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. Sodium tetradecyl sulfate is the active component of the sclerosant drug Sotradecol. Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent. Sotradecol® (sodium tetradecyl sulfate injection) is indicated in
the treatment of small uncomplicated varicose veins of the lower
extremities that show simple dilation with competent valves. The
benefit-to-risk ratio should be considered in selected patients who are great surgical risks. Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation. In the UK, Ireland, Italy, Australia, New Zealand and South Africa, it is sold under the trade-name Fibro-Vein in concentrations of 0.2%, 0.5%, 1.0%, and 3%
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0007596 |
|||
Target ID: CHEMBL4444 |
|||
Target ID: P07225 Gene ID: 5627.0 Gene Symbol: PROS1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SOTRADECOL Approved UseSotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. Launch Date1946 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Extensive muscle necrosis and infection following treatment of a lower extremity vascular malformation with Sotradecol and absolute ethanol. | 2010-07 |
|
| Inadvertent injection of sodium tetradecyl sulfate during placement of mental nerve block: discussion of management and outcome. | 2009-12 |
|
| Chronic facial pain following injection of sodium tetradecyl sulphate into an intraparotid haemolymphangioma. | 2008-09 |
|
| [Cardiorespiratory arrest after injection of Trombovar (sodium tetradecyl sulfate)]. | 1993-09-01 |
|
| Sclerosant treatment of varicose veins and deep vein thrombosis. | 1984-11 |
Sample Use Guides
Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5866042
Sodium tetradecyl sulfate inhibited flagellation, motility, swarming, and growth of Proteus (inhibitory concentration, 0.1 to 0.5 mmoles per liter). At a concentration of 0.1 mmole per liter, sodium tetradecyl sulfate completely inhibited the motility of Proteus in the liquid medium employed without impairing growth.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:05 GMT 2025
by
admin
on
Mon Mar 31 18:31:05 GMT 2025
|
| Record UNII |
6326W0DRHY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8771
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
1370424
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | RxNorm | ||
|
75275
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
6326W0DRHY
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
300-52-7
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
DTXSID7047015
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
6326W0DRHY
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
DB11328
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |